✦ LIBER ✦

Application of New French Guidelines for Economic Evaluations: A Cost-Effectiveness Analysis of Apixaban in Patients with Non-Valvular Atrial Fibrillation in France

✍ Scribed by Durand-Zaleski, I.; Cotté, F.E.; Lanitis, T.; Godard, C.; Kachaner, I.; Kongnakorn, T.; Gaudin, A.F.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-Effectiveness Analysis of Apixaban

✍ Betegón Nicolás, L.; Escolar Albaladejo, G.; Canal Fontcuberta, C.; de Salas-Can 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

Cost-Effectiveness Analysis of Apixaban

✍ Canal Fontcuberta, C.; Escolar Albaladejo, G.; Betegón Nicolás, L.; de Salas-Can 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

Comparison of cost-effectiveness of anti

✍ Krejczy, Martin; Harenberg, Job; Marx, Svetlana; Obermann, Konrad; Frölich, Lutz 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 461 KB

Economic evaluation of dabigatran for st

✍ Silva Miguel, Luís; Rocha, Evangelista; Ferreira, Jorge 📂 Article 📅 2013 🏛 Elsevier ⚖ 703 KB

Cost-effectiveness of rivaroxaban for th

✍ Asukai, Y.; Maniadakis, N.; Carcedo, D.; Lukac, M.; Evers, T. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

PCV60 Cost-Effectiveness of Dabigatran f

✍ D. Tilden; P. Germanos; J. Gordon; L. Tocchini; B. Monz 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB